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ABSTRACT
Transporters responsible for hepatic uptake and biliary clear-
ance (CLBile) of rosuvastatin (RSV) have been well characterized.
However, the contribution of basolateral efflux clearance
(CLBL) to hepatic and systemic exposure of RSV is unknown.
Additionally, the appropriate design of in vitro hepatocyte efflux
experiments to estimate CLBile versus CLBL remains to be
established. A novel uptake and efflux protocol was developed
in sandwich-cultured hepatocytes (SCH) to achieve desired tight
junction modulation while maintaining cell viability. Subse-
quently, studies were conducted to determine the role of CLBL in
the hepatic disposition of RSV using SCH from wild-type (WT)
and multidrug resistance-associated protein 2 (Mrp2)-deficient
(TR2) rats in the absence and presence of the P-glycoprotein
and breast cancer resistance protein (Bcrp) inhibitor elacridar
(GF120918). RSV CLBile was nearly ablated by GF120918 in TR
2
SCH, confirming that Mrp2 and Bcrp are responsible for the
majority of RSV CLBile. Pharmacokinetic modeling revealed that
CLBL and CLBile represent alternative elimination routes with
quantitatively similar contributions to the overall hepatocellular
excretion of RSV in rat SCH under baseline conditions (WT
SCH in the absence of GF120918) and also in human SCH.
Membrane vesicle experiments revealed that RSV is a substrate
of MRP4 (Km 5 21 6 7 mM, Vmax 5 1140 6 210 pmol/min per
milligram of protein). Alterations in MRP4-mediated RSV CLBL
due to drug-drug interactions, genetic polymorphisms, or disease
states may lead to changes in hepatic and systemic exposure of
RSV, with implications for the safety and efficacy of this commonly
used medication.
Introduction
Hepatic transport plays an important role in the pharma-
cokinetics and pharmacodynamics of rosuvastatin (RSV)
because the liver is the target organ for pharmacologic
activity, as well as the primary organ of elimination. Hepatic
clearance accounts for 72% of total RSV clearance after an
intravenous dose in humans (Martin et al., 2003). A number of
transport proteins mediating RSV disposition in the liver
have been characterized. Active uptake into hepatocytes is
facilitated by multiple organic anion transporting polypeptide
(OATP) isoforms; sodium-taurocholate cotransporting poly-
peptide also has been reported to play a role (Ho et al., 2006;
Abe et al., 2008; Kitamura et al., 2008). MRP2 and BCRP are
the canalicular proteins primarily responsible for RSV biliary
excretion (Huang et al., 2006; Kitamura et al., 2008; Keskitalo
et al., 2009; Jemnitz et al., 2010; Hobbs et al., 2012). The role
of basolateral transport proteins in RSV efflux from hepato-
cytes back into sinusoidal blood has not been examined.
Hepatic basolateral efflux of RSV could be clinically relevant
because impaired hepatic transport resulting from drug-drug
interactions and genetic polymorphisms has been shown to
alter the pharmacokinetics of RSV (Schneck et al., 2004;
Simonson et al., 2004; Zhang et al., 2006; Kiser et al., 2008;
Kitamura et al., 2008; Keskitalo et al., 2009; Hobbs et al.,
2012). Some of these changes have been associatedwith altered
efficacy (i.e., lowering of low-density lipoprotein) of RSV
(Simonson et al., 2003; Tomlinson et al., 2010), and increased
systemic exposure has been associated with life-threatening
rhabdomyolysis, which is related to statin use in general
(Hamilton-Craig, 2001; Thompson et al., 2003). Candidate
basolateral efflux transporters for RSV include MRP3 and
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MRP4, which mediate hepatic basolateral excretion of drugs
and metabolites, particularly as a compensatory route of ex-
cretion under cholestatic conditions (Scheffer et al., 2002; Denk
et al., 2004; Gradhand et al., 2008; Chai et al., 2012).
Sandwich-cultured hepatocytes (SCH) typically are used to
evaluate vectorial transport into bile and differentiate the
roles of active uptake and biliary excretion by modulating
tight junctions in the presence (cells 1 bile) or absence (cells)
of divalent cations (Ca21/Mg21) in the experimental buffer
system (B-CLEAR technology; Qualyst Transporter Solutions,
Durham, NC). A number of pharmacokinetic parameters can
be calculated from uptake data (typically evaluated over a time
period of 10 minutes), including the total substrate accumula-
tion in cells1 bile and cells, biliary excretion index, and in vitro
clearance for uptake (CLUptake) and/or biliary excretion (CLBile),
which can be used to predict in vivo clearance values based on
scaling factors such as protein content and hepatocellularity
(Swift et al., 2010a). Less frequently, the SCH model has been
used to assess efflux by preloading cells with substrates
(6 inhibitors), followed by an efflux phase, and quantifying
substrate in cells 1 bile, cells, and/or appearance in buffer
(Jemnitz et al., 2010; Swift et al., 2010b). However, the SCH
system has not been characterized under these conditions. In
a “simplified” conception of the SCH system, maintenance of
tight junctions in the presence of Ca21 would completely seal
the bile networks, and efflux experiments would reflect only
basolateral efflux clearance (CLBL) (Fig. 1A(i), upper Hepato-
cyte Scheme. Solid efflux arrows). Efflux in the absence of
Ca21 with disrupted tight junctions would reflect basolateral
plus biliary efflux and would be greater than efflux in the
presence of Ca21 (Fig. 1A(ii-iii), lower Hepatocyte Scheme). In
reality, the SCHmodel is dynamic, with regular and extensive
Fig. 1. (A) Scheme depicting preliminary studies designed to evaluate and optimize tight junction modulation throughout the uptake/efflux protocol in
the presence of standard (Std; +Ca2+) Hanks’ balanced salt solution (HBSS) (i) and two potential schemes for conducting efflux in Ca2+-free conditions:
(ii) preincubation and uptake exclusively in Std HBSS, followed by a brief wash and efflux in Ca2+-free HBSS; or (iii) maintaining open tight junctions
throughout the study period by preincubating in Ca2+-free HBSS, then performing an uptake phase in Std HBSS to provide relief from the removal of Ca2+,
followed by a brief wash and efflux in Ca2+-free HBSS. Gray shading represents inclusion of substrate in HBSS during the uptake phase. Cell schemes on the
right represent the intended condition of the SCH system during the efflux phase, with arrows depicting the potential pathways leading to substrate efflux
from cells + bile (i) and cells (ii and iii), where CLBL represents basolateral efflux, CLBile represents biliary excretion, and KFlux represents flux from the bile
networks (cells + bile only). (B) Fluorescence intensity of carboxydichlorofluorescein (CDF) in bile networks observed after administration of 1 mM CDF
diacetate (CDFDA) according to the schemes depicted in (A).
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“pulsing” of the bile canaliculi, similar to reports in hepatocyte
couplets and cultured hepatocytes (Boyer et al., 1988; Shinoda
et al., 1998). Thus, the appearance of substrate in buffer in the
presence of Ca21 reflects CLBL plus periodic flux of accumu-
lated substrate within the bile spaces (KFlux; Fig. 1A(i),
Hepatocyte Scheme). To deconvolute these data and elucidate
the contributions of CLUptake, CLBile, CLBL, and KFlux,
a pharmacokinetic modeling approach can be applied to
SCH data (Liu et al., 1999; Hoffmaster et al., 2005; Lee et al.,
2010; Yang and Brouwer, 2012; Pfeifer and Brouwer, 2013).
The purpose of the present studies was to determine the
appropriate conditions for conducting efflux studies in the
SCH system. A novel uptake/efflux protocol was developed to
determine RSV disposition in rat and human SCH. This
method, combined with pharmacokinetic modeling, revealed
that basolateral and biliary clearance represent alternative
elimination routes with a quantitatively similar contribution
to the overall hepatocellular excretion of RSV in rat and human
SCH. The role and influence of certain transporters in the
basolateral and canalicular (biliary) efflux of RSV were explored
in the SCH system, as well as in isolated expression systems.
Materials and Methods
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO)
unless otherwise stated. Nonradiolabeled RSV was purchased from
Toronto Research Chemicals Inc. (Toronto, ON, Canada), MK-571 was
purchased from Cayman Chemicals (Ann Arbor, MI). [3H]Estradiol-17-
b-D-glucuronide (E217G) and [
3H]dehydroepiandrosterone sulfate
(DHEAS) were purchased from PerkinElmer Life and Analytical
Sciences (Waltham, MA); [3H]RSV was purchased from American
Radiolabeled Chemicals, Inc. (St. Louis,MO). GF120918 (elacridar) was
a generous gift from GlaxoSmithKline (Research Triangle Park, NC).
Animals. Male Wistar wild-type (WT) rats (250–350 g) from
Charles River Laboratories (Wilmington, MA) or male Mrp2-
deficient (TR2) rats bred at the University of North Carolina (250–350 g;
breeding stock obtained from Dr. Mary Vore, University of Kentucky,
Lexington, KY) were used as donors for hepatocyte studies. Rats were
allowed free access to water and food and acclimated for a minimum of 1
week before experimentation. All animal procedures complied with the
guidelines of the Institutional Animal Care and Use Committee
(University of North Carolina, Chapel Hill, NC). All procedures were
performed with the animals under full anesthesia with ketamine/
xylazine (140/8 mg/kg i.p.).
Sandwich-Cultured Hepatocytes. Freshly isolated rat and
human hepatocytes were seeded in 24-well BioCoat plates (BD
Biosciences, San Jose, CA) at a density of 0.35 106 cells/well (WT rat
and human) or 0.2  106 cells/well (TR2 rat). Hepatocytes were
overlaid with Matrigel basement membrane matrix (BD Biosciences)
in a sandwich configuration and maintained as described previously
(Swift et al., 2010a). Human hepatocytes were purchased from Life
Technologies (Research Triangle Park, NC) or kindly provided by Life
Technologies or Triangle Research Laboratories (Research Triangle
Park, NC). Hepatocyte donors consisted of one Caucasian man, one
Caucasian woman, and one African American woman, ranging in age
from 20 to 55 years; their body mass index was 19–30.8 kg/m2. On day
4 (rat) or day 7 (human), SCH were preincubated for 10 minutes in
0.5 ml/well standard (Ca21-containing) or Ca21-free Hanks’ balanced
salt solution (HBSS). Incubating SCH in Ca21/Mg21-free buffer
containing EGTA (hereafter referred to as Ca21-free HBSS) disrupts
the tight junctions that form the bile canalicular networks (B-CLEAR
technology; Qualyst Transporter Solutions).
Preliminary studies were performed to optimize the uptake/efflux
protocol and evaluate tight junction modulation using two potential
schemes for conducting efflux studies in SCH under Ca21-free
conditions [Fig. 1A(ii)]: preincubation and uptake exclusively
in standard (1Ca21) HBSS, followed by a brief wash and efflux in
Ca21-free HBSS or [Fig. 1A(iii)] maintaining open tight junctions
throughout the study period by preincubating in Ca21-free HBSS,
then performing an uptake phase in standard HBSS (,30 minutes) to
provide relief from the removal of Ca21, followed by a brief wash and
efflux in Ca21-free HBSS. The uptake/efflux protocol described in Fig.
1A was characterized using 1 mM carboxydichlorofluorescein (CDF)
diacetate (CDFDA), and fluorescence intensity of CDF in bile
networks was observed by serial imaging using a Zeiss Axiovert
100TV inverted fluorescent microscope (Carl Zeiss Inc., Thornwood,
NY) as depicted in Fig. 1B.
For uptake and efflux studies with RSV, SCH were treated with
0.1 or 1 mM [3H]RSV (100 nCi/ml) in the absence or presence of
GF120918 (0.5 mM) in standard HBSS for 20 minutes at 37°C. After
the 20-minute uptake phase, buffers containing RSV were removed,
cells were washed twice with 37°C standard or Ca21-free HBSS buffer
without RSV, and the third application of buffer was added to SCH for
the 15-minute efflux phase (Fig. 1A). For conditions in the presence of
inhibitor, 0.5 mM GF120918 was maintained in the incubation buffer
for the duration of the experiment (preincubation, uptake, and efflux
phases). Preliminary studies indicated that 0.5 mM GF120918 was
sufficient to inhibit RSV biliary excretion in SCH with minimal
impact on uptake. RSV accumulation in cells1 bile, cells, and medium
(standardHBSS or Ca21-free HBSS buffer) during uptake (2, 5, 10, and
20 minutes) and efflux (2, 5, 10, and 15 minute) phases were
determined by terminal sampling of n5 3 wells at each time point. In
all cases, incubationmediumwas collected at the end of the incubation
period, and cells were washed twice in ice-cold HBSS. Cells were
solubilized in 0.3 ml of 0.5% Triton X-100 and radioactivity in cell
lysates and buffer samples was quantified by liquid scintillation
counting (Packard TriCarb; PerkinElmer Life and Analytical Scien-
ces). Leakage of lactate dehydrogenase (LDH) into buffer during the
uptake/efflux protocol was measured to assess cell viability through-
out the study period using the LDH Cytotoxicity Detection Kit (Roche
Diagnostics, Indianapolis, IN). LDH release was evaluated as a per-
centage of total cellular LDH content, represented by values mea-
sured after complete cell lysis using 0.5% Triton X-100 (Fig. 2).
Pharmacokinetic Modeling. Pharmacokinetic modeling and
simulation were used to evaluate RSV disposition in SCH studies
and to determine the effects of GF120918 and loss of Mrp2 function
on RSV hepatobiliary disposition in rat SCH. A model scheme in-
corporating linear parameters governing RSV flux (Fig. 3) was fit to
mass versus time data from individual SCH experiments (Figs. 4 and
5). The model fitting was performed with PhoenixWinNonlin, v6.1 (St.
Louis, MO) using the stiff estimation method and a proportional
model to account for residual error. The following differential
equations, which were developed based on the model scheme depicted
in Fig. 3, were fit simultaneously to data generated in SCH in the
presence of intact and disrupted bile canaliculi for each condition (WT
and TR2, 6 GF120918):
Mass in buffer (Standard HBSS):
dX 1Buffer
dt
5 CLBL  C1Cell 1 KFlux  XBile 2CLUptake  C1Buffer
2KWash  X 1Buffer X 1 sBuffer 5Xdose
Mass in buffer (Ca21-free HBSS):
dX 2Buffer
dt
5 ðCLBL 1 CLBileÞ  C2Cell 2CLUptake  C2Buffer
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Mass in bile (standard HBSS):
dXBile
dt
5 CLBile  C1Cell 2 KFlux  XBile X
s
Bile 50









where variables and parameters are defined as in Fig. 3 and Kwash
was activated for 1.5 minutes at the end of the 20-minute uptake
phase and fixed at 1  104 min21 based on simulations to eliminate
the RSV dose from the buffer compartment and represent the wash
step. CCell represents the intracellular concentration, calculated as
XCell/VCell, where cellular volume (VCell) was estimated based on the
protein content of each preparation using a value of 7.4 ml/mg protein
(Lee and Brouwer, 2010). CBuffer represents the buffer concentration,
calculated as XBuffer/VBuffer, where the buffer volume (VBuffer) was
constant (0.5 ml). Initial parameter estimates were obtained from
noncompartmental analysis of SCH data, where CLUptake was esti-
mated from the initial (2minutes) uptake data, CLUptake5 (dXcells1 bile/dt)/
CBuffer and CLBL and CLBile were estimated from efflux phase data under
Ca21-free conditions, where (CLBL 1 CLBile) 5 X
2
Buffer,0–15min/
area under the curve (AUC)cells,0–15min× KFlux, which represents the
flux of substrate out of bile networks in standard HBSS conditions,
was estimated initially from simulations using Berkeley-Madonna.
Sensitivity analysis of parameter estimates on model output (RSV
accumulation in cells 1 bile and cells at the end of the 20-minute
uptake phase; efflux into buffer at the end of the 15-minute efflux
phase) was conducted in Berkeley-Madonna v.8.3.11. Parameters
representing transport-mediated clearance processes were adjusted
in isolation up to 10-fold in either direction of the values describing
RSV disposition in WT (control) rat SCH (Table 1); resulting changes
in predicted cellular accumulation and efflux into buffer are shown
in Fig. 6.
Membrane Vesicles. HumanMRP3 plasmid (pcNDA3.1(2)-MRP3)
and MRP4 plasmid (pcDNA3.1(2)-MRP4) were kindly provided by
Dr. Susan Cole (Queen’s University, Kingston, ON, Canada) and
Dr. Dietrich Keppler (German Cancer Research Center, Heidelberg,
Germany), respectively. Transiently transfected human embryonic
kidney cells (HEK293T) were generated and membrane vesicles were
prepared as described previously (Leslie et al., 2001). Transport
experiments were carried out by a rapid filtration assay as described
previously (Ghibellini et al., 2008). In brief, membrane vesicles (10 mg of
protein) were incubated at 37°C with test compound in Tris-sucrose
buffer (TSB; 50 mM Tris-HCl, 250 mM sucrose, 10 mM MgCl2, 10 mM
creatine phosphate, 100 mg/ml creatine kinase, 4 mMATP or AMP), and
20 mM [3H]E217G (0.4 mCi/mL) for MRP3, 2 mM [
3H]DHEAS (0.7 mCi/ml)
for MRP4, or 0.1–100 mM [3H]RSV (0.5 mCi/ml), in a volume of 50 ml.
After incubation for 10 minutes, the reaction was stopped by the ad-
dition of 0.45 ml of ice-cold TSB and immediately applied to a glass fiber
filter (type A/E; Pall Corp., Port Washington, NY) and washed twice
with 2 ml of ice-cold TSB. Filters were mixed by vortexing in 5 ml of
scintillation fluid, and radioactivity was quantified by liquid
scintillation counting (Packard TriCarb; PerkinElmer Life and Analyt-
ical Sciences). The ATP-dependent uptake of substrate was calculated
by subtracting substrate uptake in the presence of AMP from substrate
uptake in the presence of ATP. Membrane vesicles from nontransfected
(NT) cells were used to quantify endogenous ATP-dependent uptake
of probe substrates. Inhibition data are presented as the percentage of
the prototypical substrate (E217G or DHEAS) uptake in membrane
vesicles prepared from cells overexpressing MRP3 or MRP4. Transport
of RSV by MRP4 is presented as ATP-dependent uptake, after sub-
tracting endogenous ATP-dependent uptake in NT vesicles. All data are
expressed as mean 6 S.D. of triplicate determinations in a single
experiment.
Data Analysis. The effect of Mrp2 status (WT or TR2) and
GF120918 on RSV disposition in SCH experiments was determined
by one-way analysis of variance with Tukey’s post hoc test. The effect
of Mrp2 status was evaluated at each level of inhibitor (absent or
present), and the effect of GF120918 was evaluated at each level of
Mrp2 status (WT or TR2).
Results
SCH. Preliminary studies conducted to evaluate tight
junction modulation and to optimize the uptake/efflux pro-
tocol are shown in Fig. 1. After CDFDA administration,
fluorescence microscopy confirmed that CDF accumulated in
bile networks during the uptake phase following preincuba-
tion in standard HBSS [Fig. 1B(i), Uptake Phase), but not in
SCH preincubated in Ca21-free HBSS [Fig. 1B(iii), Uptake
Phase] as a result of the disruption of bile networks in the
absence of calcium. CDF fluorescence intensity in bile net-
works was maintained throughout the uptake and efflux
phase in the presence of standard HBSS [Fig. 1B(i), Efflux
Phase in Standard HBSS]. CDF fluorescence was not visible
in bile networks throughout the uptake and efflux phase in
Ca21-free HBSS [Fig. 1B(iii)]. In contrast, disappearance
of CDF fluorescence intensity in bile networks after
Fig. 2. Lactate dehydrogenase (LDH) release versus time in rat (A) and
human (B) sandwich-cultured hepatocyte (SCH) experiments performed
according to the scheme depicted in Fig. 1A(i) and (iii) during the uptake
and efflux phase, respectively. Closed symbols represent SCH treated in
standard (+Ca2+) Hanks’ balanced salt solution (HBSS) with intact bile
networks, whereas open symbols represent cells treated with Ca2+-free
HBSS during the preincubation and efflux phase with open bile networks
maintained throughout the study period. Data are reported as mean6 S.E.
M. (n = 3 SCH preparations in triplicate).
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switching from standard HBSS to Ca21-free HBSS at
the wash phase suggested a time frame of ∼5 minutes
for opening of bile networks [Fig. 1B(ii), Efflux Phase in
Ca21-free HBSS]. As a measure of cell viability during the
uptake/efflux protocol, less than 4% and 7% of total cellular
LDH content was released over the 35-minute experimental
time course in both rat and humanSCH, respectively, as shown
in Fig. 2.
The mass-time profiles of RSV in cells 1 bile, cells, and
buffer during the optimized uptake/efflux protocol described
in Fig. 1A(i) and (iii) are plotted in Fig. 4. After 20-minute
treatment (standard HBSS) of WT and TR2 SCH with 0.1 or
1 mM [3H]RSV in the absence or presence of GF120918
(0.5 mM), RSV accumulation in cells1 bile and cells increased
during the uptake phase and decreased during the efflux
phase, whereas the appearance in the buffer increased during
the efflux phase. RSV accumulation in bile networks (the
difference between accumulation in cells 1 bile and cells) was
reduced in Mrp2-deficient TR2 SCH, and biliary excretion
nearly was ablated in TR2 SCH in the presence of GF120918.
Parameter estimates recovered from simultaneously fitting
differential equations based on the model scheme in Fig. 3
to data at both 0.1 and 1 mM RSV concentrations from
independent SCH preparations are listed in Table 1. CLBile
was significantly different between groups (F-value 38.2, P ,
0.0001). The effect of Mrp2 status (WT vs. TR2) was statis-
tically significant in the absence and presence of GF120918;
similarly, the effect of GF120918 was statistically significant
in WT and TR2 SCH. The CLBL term was significantly differ-
ent between groups (F-value5 3.92, P, 0.048). However, the
individual effect of animal and GF120918 failed to reach sig-
nificance after correcting for multiple comparisons. CLUptake
was not different between groups (F-value 5 1.48, P 5 0.28).
There was a trend toward decreased CLUptake and increased
CLBL in TR
2 compared with WT hepatocytes in both the
Fig. 3. Model schemes depicting the disposition of rosuvastatin (RSV) in
sandwich-cultured hepatocyte (SCH) studies based on the experimental
design depicted in Fig. 1A(i) and (iii). X denotes mass of RSV, V denotes
compartmental volume, C denotes compartmental concentration; sub-
scripts on mass, volume and concentration terms denote the corresponding
compartment in the model scheme; superscripts represent the presence (+;
intact tight junctions, cells + bile) and absence (2, modulated tight junctions,
cells) of Ca2+ in the incubation buffer; clearance values are designated as
CLUptake for uptake from buffer into hepatocytes, CLBL for efflux from
hepatocytes into buffer, CLBile for canalicular excretion from hepatocytes,
and KFlux for flux from bile networks into buffer.
Fig. 4. [3H]Rosuvastatin (RSV) mass versus time data in wild type (WT) and Mrp2-deficient (TR2) rat sandwich-cultured hepatocytes (SCH) in the
absence (control) or presence of GF120918 during the uptake and efflux phase. Closed symbols/solid lines represent [3H]RSV in cells + bile (standard
HBSS), and open symbols/dashed lines represent [3H]RSV in cells (Ca2+-free HBSS). The simulated mass-time profiles were generated from the relevant
equations based on the model scheme depicted in Fig. 3, and the final parameter estimates reported in Table 1. Data (pmol/well) are reported as mean6
S.E.M. (n = 3 to 4 SCH preparations in triplicate per group).
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absence and presence of GF120918. Interestingly, GF120918
tended to decrease both CLUptake and CLBL in WT and TR
2
SCH. The KFlux term was significantly different between
groups (F-value 5 7.22, P , 0.01); KFlux was significantly
increased in TR2 SCH in the absence of GF120918. The effect
of GF120918 on KFlux was statistically significant in TR
2 but
not WT SCH. An important finding is that the parameter
estimates revealed that CLBL and CLBile have a similar
contribution to the total cellular excretion of RSV under base-
line conditions (WT SCH in the absence of GF120918).
Uptake of 1 mM RSV and subsequent efflux were examined
in SCH from three human liver preparations (Fig. 4). Pa-
rameter estimates recovered from fitting the differential
equations based on the model scheme depicted in Fig. 3 to
data from independent human SCH preparations are listed in
Table 1. CLUptake was at least an order of magnitude greater
than the efflux pathways (CLBL and CLBile)), which were of
similar magnitude; CLBL was approximately 3-fold greater
than CLBile in human SCH. KFlux was similar to the value
observed in rat SCH.
Sensitivity Analysis. Sensitivity analysis of parameter
estimates on model output was conducted; resulting changes
in simulated cellular accumulation and efflux into buffer are
shown in Fig. 6. Cellular accumulation at the end of the
uptake phase was most sensitive to CLUptake in the absence
and presence of Ca21. The amount of substrate in buffer at the
end of the efflux phase was most sensitive to increased CLBile
in Ca21-free conditions, whereas efflux in the presence of
Ca21 was most sensitive to CLUptake across a range of values
and also to increased CLBL. Cellular accumulation and efflux
into buffer in the absence of Ca21 were not affected by KFlux
since bile networks are disrupted in Ca21-free HBSS.
MRP3- and MRP4-Mediated Transport in Membrane
Vesicles. The inhibitory potential and substrate specificity
of RSV for MRP3 and MRP4 were evaluated using membrane
vesicles prepared from NT- and MRP-overexpressing
HEK293T cells. Pilot studies confirmed that ATP-dependent
uptake was linear up to 5 and 2 minutes for the prototypical
MRP3 and MRP4 probe substrates, E217G and DHEAS,
respectively (data not shown). ATP-dependent uptake de-
termined at 1minute was concentration-dependent with aKm
and Vmax of 23 6 5 mM and 1700 6 200 pmol/min per
milligram protein, respectively, for E217G, and 2.9 6 0.2 mM
and 3906 40 pmol/min per milligram of protein, respectively,
for DHEAS (mean 6 S.D.). Coincubation with 50 mM RSV
inhibited ATP-dependent transport of the prototypical MRP3
and MRP4 probe substrates, E217G (20 mM) and DHEAS
(2 mM), by 766 2% and 886 5%, respectively (Fig. 7, A and B).
By comparison, ATP-dependent transport of E217G (20 mM)
and DHEAS (2 mM) was 77 6 3% and 88 6 5% lower in NT
membrane vesicles and decreased by 986 2% and 1056 3% in
the presence of the potent pan-MRP inhibitor, MK-571 (50 mM,
Fig. 7, A and B). ATP-dependent transport of 0.1 mMRSV was
linear up to ∼1 minute and was greater in membrane vesicles
from HEK293T cells overexpressing MRP4 and MRP3 com-
pared with NT cells (Fig. 7C). Uptake of RSV at 1 minute in
membrane vesicles from MRP4-overexpressing cells was
concentration-dependent with a Km and Vmax of 21 6 7 mM
and 1140 6 210 pmol/min per milligram of protein for MRP4
Fig. 5. [3H]Rosuvastatin (RSV) mass versus time data in human
sandwich-cultured hepatocytes (SCH) during the uptake and efflux phase.
Closed symbols/solid lines represent [3H]RSV mass in cells + bile
(standard HBSS), and open symbols/dashed lines represent [3H]RSVmass
in cells (Ca2+-free HBSS). The simulated mass-time profiles were gen-
erated from the relevant equations based on the model scheme depicted in
Fig. 3B and the final parameter estimates reported in Table 1. Data (pmol/
well) are reported asmean6 S.E.M. (n = 3 SCH preparations in triplicate).
TABLE 1
Summary of recovered parameter estimates and residual error based on the model scheme depicted in
Fig. 3 describing rosuvastatin (RSV) disposition in sandwich-cultured hepatocytes (SCH) from wild-type
(WT) and Mrp2-deficient (TR2) rats in the absence (control) or presence of GF120918 and in human
SCH
SCH were treated with 0.1 and 1 mM RSV in rat SCH, and 1 mM RSV in human SCH (see Fig. 1A(i) and (iii) for details of
incubation conditions) and the model was fit simultaneously to all data from each preparation. Data are presented as
mean 6 S.D. of individual fits from n = 3 to 4 SCH preparations. A proportional error model was used, with a mean





Control 9.5 6 2.7 0.21 6 0.07 0.23 6 0.04 0.057 6 0.029
+GF120918 7.9 6 1.0 0.16 6 0.03 0.079 6 0.017† 0.046 6 0.007
TR2 SCH
Control 7.6 6 1.2 0.34 6 0.09 0.089 6 0.025* 0.093 6 0.008*
+GF120918 6.6 6 1.6 0.27 6 0.06 0.018 6 0.015*† 0.049 6 0.027†
Human SCH 1.4 6 0.3 0.10 6 0.02 0.037 6 0.015 0.044 6 0.035
# CLBL was significantly different between groups in rat SCH (F-value = 3.92, P, 0.048), but individual effects of Mrp2
status and GF120918 failed to reach significance after correcting for multiple comparisons.
* P , 0.05, adjusted: effect of Mrp2 status (WT vs. TR2) is statistically significant within the same level of inhibitor
(control or +GF120918).
† P , 0.05, adjusted: effect of GF120918 (absence vs. presence) is statistically significant within the same level of Mrp2
status (WT or TR2).
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(Fig. 7D). Despite inhibition of MRP3-mediated E217G trans-
port by 50 mM RSV (Fig. 7A) and apparent MRP3-dependent
RSV uptake at low concentrations (Fig. 7C), ATP-dependent
uptake of RSV over a range of concentrations in membrane
vesicles fromMRP3-overexpressing cells was not significantly
greater than uptake into vesicles prepared fromNT cells (data
not shown).
Discussion
The present studies suggest for the first time a significant
role for basolateral efflux in the hepatocellular elimination of
RSV from rat and human hepatocytes. Examination of this
basolateral efflux process was possible using a novel protocol
in SCH. Uptake and efflux profiles observed in SCH with
maintenance of tight junctions in the closed (standard HBSS,
cells1 bile) or open (Ca21-free HBSS, cells) conformation over
35 minutes, and the behavior of the system under these
conditions, was characterized for the first time.
At least two potential schemes exist for the design of efflux
studies in Ca21-free conditions in SCH [Fig. 1A(ii) and (iii)].
One is to preincubate and perform the uptake phase in
standard (1Ca21) HBSS, followed by a brief wash and efflux
in Ca21-free HBSS [Fig. 1A(ii)] (Jemnitz et al., 2010; Swift
et al., 2010b). A limitation of this approach is that substrate
accumulation in bile networks during the uptake phase may
not be washed away completely before initiating the efflux
phase in Ca21-free HBSS. Based on the disappearance of CDF
fluorescence intensity in bile networks [Fig. 1B(ii), Efflux
Fig. 6. Sensitivity analysis of parameter estimates
determined from the model depicted in Fig. 3. Param-
eters were altered 10-fold in either direction of the
values estimated for mean control data (Table 1), and
the -fold change in the predicted model output was
examined. Model output included rosuvastatin (RSV)
accumulation in cells + bile or cells at the end of the
20-minute uptake phase (lysate; top panel) and RSV
efflux into buffer at the end of the 15-minute efflux
phase (buffer; bottom panel). Solid lines represent
incubations in standard HBSS (cells + bile), and dashed
lines represent incubations in Ca2+-free HBSS (cells).
Fig. 7. ATP-dependent uptake of (A) 20 mM [3H]estradiol-
17-b-D-glucuronide (E217G) or (B) 2 mM [
3H]dehydroepian-
drosterone sulfate (DHEAS) in membrane vesicles from
nontransfected (NT) and MRP3- or MRP4-overexpressing
(control) human embryonic kidney (HEK293T) cells, re-
spectively, and inhibition by 50 mM rosuvastatin (RSV) and
MK-571. (C) Time-dependent transport of [3H]RSV in
membrane vesicles from NT (d) MRP3- (m) and MRP4- (j)
overexpressing cells. (D) Concentration-dependent trans-
port of RSV in membrane vesicles from MRP4-overexpressing
HEK293T after subtracting endogenous ATP-dependent up-
take in vesicles from NT cells; Vmax and Km values were
obtained from nonlinear regression analysis. In all cases, data
represent mean 6 S.D. of triplicate measurements in a single
experiment.
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Phase], the time required for complete opening of canalicular
networks is 2–5 minutes. Before this time, efflux into the
buffer in Ca21-free HBSS reflects, in part, content from the
opening of bile networks. Another potential design for efflux
studies involves maintaining open tight junctions throughout
the study period. This is accomplished by preincubating in
Ca21-free HBSS and then performing the uptake phase in
standard HBSS to provide relief from prolonged exposure to
Ca21-free conditions, followed by a brief wash and efflux in
Ca21-free HBSS [Fig. 1A(iii)]. A limitation with this method
is potential resealing of the tight junctions during Ca21
repletion throughout the uptake phase (Liu et al., 1999).
However, imaging with CDF suggests that resealing of the
tight junctions allowing substrate accumulation in the bile
networks is minimal over the 20-minute uptake phase [Fig.
1B(iii)]. Therefore, based on the data generated, preincubat-
ing SCH in standard or Ca21-free HBSS before performing
the uptake phase in standard HBSS, followed by a brief wash
and then efflux in standard or Ca21-free HBSS [Fig. 1A(i) and
(iii)], is the most appropriate method for conducting efflux
studies in the SCH system. It should be noted that phar-
macokinetic modeling of the data is required to differentiate
the individual contributions of CLBL and CLBile. A potential
concern when maintaining open tight junctions in SCH
studies is the loss of cell viability resulting from prolonged
or repeated exposure to Ca21-free HBSS (Swift et al., 2010a).
In the present study, less than 4 and 7% of total cellular LDH
content was released over the 35-minute uptake/efflux
protocol in rat and human SCH, respectively (Fig. 2).
RSV cellular accumulation and appearance in buffer were
simulated to reflect 10-fold changes in parameter estimates
describing RSV disposition in rat SCH (Table 1, WT control).
The simulated data reported in Fig. 6 include RSV accumu-
lation in cells 1 bile and cells at the end of the 20-minute
uptake phase, as well as the mass of RSV in buffer at the end
of the 15-minute efflux phase. As expected, the simulated data
were least sensitive to changes in the KFlux parameter, which
was estimated solely from standard HBSS conditions because
this process is absent in Ca21-free conditions. Cellular accu-
mulation at the end of the uptake phase was most sensitive to
CLUptake. The amount of substrate in buffer at the end of the
efflux phase was most sensitive to increased CLBile and CLBL
in Ca21-free HBSS, whereas efflux in standard HBSS was
most sensitive to CLUptake values, and also to increased CLBL.
Interestingly, efflux into buffer was inversely proportional to
CLBL, and also CLBile in Ca
21-free HBSS. This may seem
paradoxical until one considers that greater efflux will
decrease cellular accumulation during the uptake phase,
which drives substrate appearance in buffer during the efflux
phase. These findings illustrate the power of a modeling and
simulation approach to analyze and interpret the data and to
characterize and understand more fully the SCH system
under conditions used to perform efflux studies.
SCH data, combined with pharmacokinetic modeling,
revealed that CLBL and CLBile represent alternative path-
ways with a quantitatively similar contribution to the total
hepatocellular excretion of RSV under normal conditions in
rat SCH; CLBL was ∼3-fold greater than CLBile in human
SCH. The effects of modulating Mrp2 and Bcrp function using
TR2 SCH and GF120918, respectively, were consistent with
previous reports suggesting that each canalicular trans-
porter contributes to a similar degree and together
constitute approximately 90–95% of RSV biliary excretion in
rat liver (Kitamura et al., 2008; Hobbs et al., 2012). GF120918
tended to inhibit both CLUptake and CLBL in rat SCH
experiments, consistent with the promiscuous nature of
transporter substrates and inhibitors. CLUptake tended to
decrease and CLBL tended to increase in TR
2 compared with
WT SCH, consistent with the hepatoprotective compensatory
changes that would be expected in the setting of impaired
biliary excretion. Indeed, it has been shown that NTCP ex-
pression is downregulated and Mrp3 upregulated in livers
from TR2 compared with WT rats (Johnson et al., 2006).
Transporter expression and function have been reported to
change over time in rat SCH. Namely, OATP expression and
function in rat SCH is decreased by 4- to 5-fold over days
in culture (Kotani et al., 2011; Tchaparian et al., 2011).
Therefore, RSV CLUptake likely is underestimated in rat SCH
(Table 1); in contrast, OATP-mediated CLUptake in human
SCH appears to be maintained over days in culture (Kotani
et al., 2011). Bcrp and Mrp2 expression have been reported to
increase and decrease, respectively, in rat SCH compared
with liver tissue (Li et al., 2009a,b, 2010). Therefore, the
effects of these changes may have minimal overall impact on
RSV CLBile. Available data suggest that expression of MRP3
and MRP4 in rat and human SCH may be relatively stable
over days in culture (Swift et al., 2010a; Ohtsuki et al., 2012;
Schaefer et al., 2012). However, robust quantitative proteo-
mics data for transport proteins that mediate CLBL are not
yet available. In addition, the CLBL and CLUptake parameters
in Table 1 represent both active and passive components of
the transport process. Given these limitations, whole liver
data are needed to aid in vitro-in vivo correlation of the CLBL
pathway. In addition, physiologically based pharmacoki-
netic modeling has been used to correlate data in human
SCH to available in vivo data (Jones et al., 2012).
Two candidate transporters that could contribute to the
basolateral excretion of RSV were examined in membrane
vesicles prepared from nontransfected HEK293T cells and
HEK293T cells overexpressing MRP3 and MRP4. MRP3 and
MRP4 transport was characterized using the prototypical
substrates, E217G and DHEAS, respectively; Km estimates
were similar to values previously reported (Zelcer et al., 2001,
2003). RSV (50 mM) inhibited the MRP3- andMRP4-mediated
transport of prototypical substrates to a similar extent as the
prototypical pan-MRP inhibitor MK-571 (Fig. 7, A and B).
Further studies performed to evaluate the ability of MRP3 and
MRP4 to transport RSV directly demonstrated that time- and
ATP-dependent uptake in membrane vesicles prepared from
MRP3- and MRP4-overexpressing cells was greater than in
vesicles fromNT cells (Fig. 7C). Concentration-dependent uptake
revealed that RSV was transported by MRP4 with a Km of
∼21 mM. Unbound RSV concentrations in human liver are
likely to be below this Km value, despite efficient hepatic
uptake and accumulation. The mean steady-state RSV
maximum total plasma concentration in humans is ∼50 ng/
ml (0.1 mM) after an 80-mg daily oral dose (Warwick et al.,
2000; Cooper et al., 2003). Accumulation (Kp) of total RSV
in human and rat hepatocytes in vitro was ∼20-fold in the
present study, consistent with previous reports (Nezasa
et al., 2003), and ∼20- to 45-fold accumulation in rat liver
in vivo (Nezasa et al., 2002), leading to estimated hepato-
cellular RSV concentrations of #5 mM in humans. At pres-
ent, the contribution of other transport proteins and passive
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diffusion to RSV CLBL in SCH cannot be ruled out because
specific MRP4 inhibitors have not been identified.
A novel uptake and efflux protocol was developed in SCH
that revealed the significant contribution of basolateral efflux
to the hepatocellular excretion of RSV in rat and human he-
patocytes. When combined with a modeling approach, this
experimental paradigm can be used to elucidate the relative
contribution of CLBL as well as CLBile. RSV is a substrate for
human MRP4, which likely contributes to the basolateral
efflux of RSV in human liver. An important note is that MRP4-
mediated efflux of RSV may be impaired due to patient-specific
factors such as drug-drug interactions, genetic variation, or
disease states. Altered function of MRP4may lead to changes in
hepatic and systemic exposure of RSV, which may impact the
efficacy and safety of RSV. The involvement of hepatic
basolateral efflux in drug disposition remains largely un-
recognized except in the case of hepatically derived drug con-
jugates. Important next steps will be to assess the basolateral
efflux of RSV and other drugs in whole liver to ascertain the
potential role of this pathway in vivo, and the predictive
capability of the current SCH method.
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